Xenetic Biosciences

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Xenetic’s mission is to revolutionize biotherapeutic production by enabling better access and product yield, allowing for better medicines to be developed for people and animals alike.

Xenetic envisions making biotherapeutics more accessible and affordable for everyone, regardless of their location or socio-economic background.

Xenetic has won several awards for its pioneering research, including the 2020 Frost & Sullivan Most Promising Company of the Year award. They are continuing to innovate in the biotherapy space and are looking to expand their research capabilities into new areas.